Last reviewed · How we verify
NCT05577741: ENVELMIND
Effect of the Enriched Environment on the Risk of Relapse
NA trial testing Multisensory virtual reality pod (SENSIKS©) in Alcoholic Relapse in 135 participants. Completed in 9 July 2025.
9 July 2025
Quick facts
| Lead sponsor | Centre Hospitalier Henri Laborit |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 135 |
| Start date | 29 November 2022 |
| Primary completion | 9 July 2025 |
| Estimated completion | 9 July 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- Multisensory virtual reality pod (SENSIKS©)
- Cognitive bike (Vélo-cognitif®)
- Standard treatment
Conditions studied
- Alcoholic Relapse — all drugs for Alcoholic Relapse →
Sponsor
Centre Hospitalier Henri Laborit
Who can join
Adults 18 to 65, any sex, with Alcoholic Relapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study investigates the effects of enriched environment on the risk of relapse in alcoholic patients. 135 patients hospitalized for an alcoholic addiction will be recruited and randomized in two groups: one group will receive standard of care, the other group will receive a treatment with enriched environment. The enriched environment consists of six sessions of virtual reality (20 minutes) in a multi-sensory pod and six sessions (20 minutes) of bike activity with cognitive tasks while pedalling. The multi-sensory virtual reality pod allows mindfulness practice and allows patients to be in immersive situations that may trigger cues in order to help them in craving management. The bike consists in the combination of a pedal set and a touch pad on which cognitive training games are offered. This tool thus makes it possible to simultaneously stimulate motor skills and cognition by means of bicycle-game coupling. Patients are then followed during 3 months and a half.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of environmental enrichment on relapse rates in patients with severe alcohol use disorder: protocol for a randomised controlled trial.
Barillot L, Chauvet C, Besnier M, Jaafari N, et al · · 2023 · cited 5× · PMID 37173113 · DOI 10.1136/bmjopen-2022-069249
Verify or expand the search:
- PubMed search for NCT05577741
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Henri Laborit trials
Trials by the same sponsor.
- NCT07429500 — tDCS and Symptom Provocation in Treatment-Resistant OCD · NA · not yet recruiting
- NCT07015502 — Self-Dehumanization and Hesitation to Report Domestic Violence · recruiting
- NCT07274722 — Influence of Control Deprivation on the Use of the Analytical Cognitive Style in Anorexic Subjects · NA · recruiting
- NCT06093919 — Study of Prevalence of Eating Disorder in Liver Transplant Patients · completed
- NCT06009523 — Effects of Transcranial Direct Current Stimulation (tDCS) in the Management of Suicidal Ideation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05577741 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Henri Laborit
- Last refreshed: 13 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05577741.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing